Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

PT-141 (Bremelanotide): What It Is Studied Alongside

Bremelanotide is a cyclic melanocortin receptor agonist studied in HSDD, obesity co-administration, diabetic kidney disease, and lactation pharmacokinetics. A research-supply summary of what the registered evidence actua

peptides-pro Editorial

Bremelanotide is a synthetic cyclic heptapeptide and a melanocortin receptor (MCR) agonist, also written as PT-141 and supplied as the acetate salt, bremelanotide acetate [1][9]. It is a macrocyclic peptide in the same structural family as setmelanotide, and the literature groups both as mid-size macrocycles that sit between small molecules and biologics in affinity, stability, and pharmacokinetic behaviour [1]. The compound is a D-amino-acid-containing peptide, a design feature associated with resistance to proteolytic degradation and increased conformational rigidity [11]. Identifiers such as sequence, formula, and molecular weight are not given in the evidence block used here, so they are not stated. The work around this molecule centres on the melanocortin receptor family, with MC4R activation the receptor event most directly probed in the registered human studies [8].

What follows is a catalogue of what bremelanotide has been studied alongside in registered research: other pharmacological agents, specific receptor subtypes, defined patient populations, and analytical methods. Where a finding comes from animals or from in vitro work, that is stated. Where the evidence block does not support a claim, the claim is left out.

Research Studies

Bremelanotide and MC4R activation in premenopausal women with HSDD

A randomised, double-blind, placebo-controlled, two-way crossover physiological study was designed to evaluate the effects of melanocortin-4 receptor (MC4R) activation on brain activity patterns and behavioural psychometric measures of sexual arousal during visual erotic stimuli [8]. The population was approximately 40 right-handed, heterosexual, premenopausal women aged 18 years and over with hypoactive sexual desire disorder (HSDD) of at least six months' duration [8]. This is the clearest registered human study in the evidence block that isolates the receptor mechanism rather than the clinical endpoint.

Bremelanotide and placebo in premenopausal women with HSDD

A Phase 3, bridging, multicentre, randomised, double-blind, placebo-controlled, parallel-group trial was set up to evaluate the efficacy and safety of subcutaneously administered bremelanotide in premenopausal women with HSDD, with or without decreased arousal [7]. The comparator is placebo, and the route is subcutaneous [7]. A separate systematic review of registered clinical trials examined emerging pharmacological therapies for HSDD in adult women, noting that pharmacological options remain limited and that individual trial evidence is heterogeneous [2].

Bremelanotide and tirzepatide in obesity

A Phase 2 study was designed to evaluate co-administration of bremelanotide with tirzepatide for the treatment of obesity [5]. It is prospective, randomised, double-blind, and placebo-controlled, in subjects with a BMI from 30.0 to 45.0 kg/m2 inclusive [5]. This is a combination design: bremelanotide is the add-on to tirzepatide therapy, not the monotherapy [5].

StudyCo-administered or compared agentPopulationDesign
NCT06565611 [5]TirzepatideAdults with BMI 30.0–45.0 kg/m2Phase 2, randomised, double-blind, placebo-controlled
NCT05709444 [6]RAAS inhibition therapyType II diabetic nephropathyPhase IIb, multicentre, open-label, prospective
NCT04943068 [7]PlaceboPremenopausal women with HSDDPhase 3, bridging, randomised, double-blind, placebo-controlled
NCT04179734 [8]Placebo (crossover)Premenopausal women with HSDDRandomised, double-blind, two-way crossover
NCT06867835 [4]None (single dose)Lactating women 10 days–6 months post-partumOpen-label pharmacokinetic

Bremelanotide and RAAS inhibition in diabetic kidney disease

A Phase IIb, multicentre, open-label, prospective study assessed bremelanotide when administered with RAAS inhibition therapy in subjects with Type II diabetic nephropathy [6]. After six months of therapy, subjects remained in the trial for further assessment and underwent a diagnostic renal biopsy to assess the effect of melanocortin therapy on diabetic histopathology at 12 months [6]. The co-administered class here is RAAS inhibition, and the tissue readout is renal histopathology rather than a serum marker [6].

Bremelanotide and breast-milk pharmacokinetics in lactating women

An open-label pharmacokinetic study was performed in 10 healthy lactating female subjects between 10 days and 6 months post-partum inclusive, given a single 1.75 mg subcutaneous dose of bremelanotide [4]. The primary objectives were to evaluate whether bremelanotide is secreted in breast milk and to measure its concentration and characterise its pharmacokinetics in that compartment [4]. Maximum participation was approximately 29 days, comprising a 3-week screening period and a 1-day treatment period [4].

Bremelanotide and macrocyclic MCR scaffolds in receptor-selectivity work

A medicinal-chemistry programme designed and synthesised 14 macrocyclic peptide analogues with 19- to 23-membered rings, based on the MT-II, SHU-9119, and PG-901 scaffolds, and assessed their pharmacological activity against human MC1R, MC3R, MC4R, and MC5R [1]. Bremelanotide and setmelanotide are cited in that work as recent clinical successes of the macrocyclic peptide modality, which the authors frame as balancing small-molecule and biologic properties [1]. This is in vitro receptor pharmacology, not a clinical finding.

Bremelanotide and analytical characterisation of its degradants

A stability-indicating RP-HPLC method was developed for bremelanotide, with degradation products characterised by LC-HRMS/MS combined with computational approaches, and epimerisation predicted through modelling [9]. The paper reports that the intrinsic stability and degradation behaviour of this cyclic peptide had not been extensively investigated [9]. This is analytical and computational work; it does not report a physiological effect.

Bremelanotide and the broader therapeutic-peptide literature

A narrative review of therapeutic peptides in gerontology covered mechanisms, clinical applications, evidence base, and safety profiles of peptides with demonstrated or potential applications in healthy aging and age-related conditions, drawing on PubMed, Scopus, and the FDA and WADA regulatory databases [3]. Bremelanotide appears in this context as one peptide among a wider class, not as the subject of a dedicated gerontology finding [3].

Bremelanotide and the HSDD trial literature

A separate analysis reports that HSDD clinical trials evaluating testosterone therapy, flibanserin, and bremelanotide spanning nearly a decade show women with HSDD encompassing a range of presentations [10]. The same paper concerns the quantification of "mercy sex" in heterosexual women [10]. It is included here as context for how the HSDD trial literature has been reviewed, not as a mechanistic finding about the compound.

Bremelanotide and male sexual arousal and desire disorders

A paper in the evidence block asks whether bremelanotide should be considered for the treatment of sexual arousal and desire disorders in men [12]. The evidence block gives only the title and topic of that paper, so no findings from it are reported here.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and we do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp